Animal Venom Pharmacological Resources: Exploiting Bioactive Peptides to Target Multi-Drug-Resistant Bacteria
Abstract
Background: The escalating rise of multi-drug-resistant (MDR) bacterial strains significantly threatens global health, creating a "silent pandemic" prompted by natural selection, gene mutation, and horizontal gene transfer. This crisis is worsened by the deficit in the development of new treatments, necessitating the innovative discovery of new potent antibacterial agents.
Objective: This review examines animal venom, a complex mixture of an evolutionary array of bioactive molecules, as an important emergent source of broad-spectrum antimicrobial peptides (AMPs), creating potential drug templates for next-generation therapeutics.
Results: We highlight numerous identified AMPs from various venomous taxa, including scorpions, snakes, spiders, frogs, bees, and wasps, characterized by their bactericidal activity against both Gram-positive and Gram-negative bacteria. They exhibit diverse mechanisms of action, characterized by rapid membrane disruption models, biofilm inhibition, bacterial enzyme dysregulation, immunomodulatory effects, and the control of intracellular targets. These bioresources serve as a structural base for the development of analogs with enhanced potency, higher selectivity, and less systemic toxicity. We also discuss repurposing strategies applied to the native AMPs, the potential application of nanoparticle technologies and the usage of computational methods.
Conclusion: These advanced approaches accelerate the examination of large databases to optimize…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.